Marksans Pharma announced that UK MHRA has granted Market
Authorisation to the Company's wholly owned subsidiary Relonchem Limited for Fluoxetine 20mg/5ml Oral Solution.
Therapeutic use of the product is for treatment of depressive illness and other mental/mood disorders.
The product will be manufactured at the plant of Bell, Sons & Co. (Druggists) located at Gifford House, Slaidburn Crescent, Southport, UK.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
